Microbiome Meeting Overview
Microbiome Meeting Overview
Malibu Microbiome Meeting | March 20, 2021
Target Audience
This activity is designed for novice to intermediate clinicians and healthcare providers who want to learn more about developments in research and patient selection.
Learning Objectives
At the completion of this activity, participants should be able to:
· Discuss the research protocol,
· Describe the clinical features of immunotherapy induced colitis,
· Describe the latest progress on methodology, safety and benefits related to FMT in conditions beyond C.diff infection,
· Recognize a basic understanding of the nature of our symbiotic biome, particularly the gut microbiome,
· Outline the basics of microbiome characteristics in health and disease,
· Discuss the results of the effect of microbiota transplant on GI and autism symptoms,
· Identify methods used to study the composition and function of the gut microbiome,
· Interpret metagenomic readout data,
· Evaluate the efficacy data of various FMT administrative methods from randomized controlled,
· Explain safety considerations around FMT and the serious adverse events which have been reported,
· Discuss the therapeutic landscape of first-generation microbiome therapies,
· Recognize the role of human-first discovery and next generation microbiome therapeutic,
· Recognize evidence behind microbiome replacement for recurrent Urinary Tract infections,
· Recognize evidence behind microbiome replacement for multi drug resistant organisms.
· Enhance new relationships with physicians with common interests throughout the world.
Activity Goal
This activity is designed to address the following core and team competencies: Patient Care, Medical Knowledge, Practice-based Learning, Ethics for Interprofessional Practice, and Interprofessional Communication.
Non-Endorsement Statement
The provider verifies that sound education principles have been demonstrated in the development of this educational offering as evidenced by the review of its objectives, teaching plan, faculty, and activity evaluation process. The provider does not endorse or support the actual opinions or material content as presented by the speaker(s) and/or sponsoring organization.
Disclosure
The provider adheres to accreditation requirements regarding industry support of continuing medical education. Disclosure of the planning committee and faculty’s commercial relationships will be made known at the activity. Speakers are required to openly disclose any limitations of data and/or any discussion of any off-label, experimental, or investigational uses of drugs or devices in their presentations. All provider employees, activity planners, and course directors in control of content have indicated that they have no relevant financial relationships to disclose.
Disclosure Summary
The provider adheres to accreditation requirements regarding industry support of continuing medical education. Disclosure of the planning committee and faculty’s commercial relationships will be made known at the activity. Speakers are required to openly disclose any limitations of data and/or any discussion of any off-label, experimental, or investigational uses of drugs or devices in their presentations. All provider employees, activity planners, and course directors in control of content have indicated that they have no relevant financial relationships to disclose.
The following speakers have indicated they have No Relevant Financial Relationships to Disclose:
Sabine Hazan MD; Scott Jackson, PhD; Andreas Papoutsis, PhD; Howard Young, PhD
Disclosed Relationships
James Adams, PhD: Finch Therapeutics – Research Grant / Licensed Patents; Consultant
Thomas Borody, MD, PhD: Finch Therapeutics – Consultant, Stockowner
Paul Feuerstadt, MD: Merck – Speakers Bureau; Rebiotix-Ferring Pharmaceuticals – Consultant,
Advisory Board; SERES Therapeutics – Advisory Board; Takeda Pharmaceuticals – Advisory Board
Colleen Kelly, MD: Finch Therapeutics – Site investigator for clinical trial
Sahil Khanna, MBBS, MS: Rebiotix, Inc – Research Support
Alexander Khoruts, MD: Finch Therapeutics – Research Grant
Neil Stollman, MD: Assembly Biopharma – Research Support
Yinghong (Mimi) Wang MD PhD: Tillotts Pharma – Consultant
Faming Zhang, MD, PhD: FMT Medical / Nanjing – Contracted Research (self and spouse); Own Patent – GenFMTer and TET device.
Accreditation
Con el fin de mejorar la atención al paciente, esta actividad ha sido planificada y puesta en marcha por Cine-Med y Medical Resource Association. Cine-Med cuenta con la acreditación conjunta del Consejo de Acreditación para la Formación Médica Continua (ACCME), el Consejo de Acreditación para la Formación Farmacéutica (ACPE) y el Centro Americano de Acreditación de Enfermeras (ANCC) para impartir formación continua al equipo sanitario.
Médicos
Ciné-Med designates this live activity for a maximum of 5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
El resto de profesionales sanitarios recibirán un certificado de participación. Para obtener información sobre la aplicabilidad y la aceptación de los certificados de participación en actividades designadas para obtener créditos AMA PRA de categoría 1™, consulte a su colegio profesional.
Certificates
To claim your CME credits, complete the online Credit and Evaluation form CLICK HERE
Participants will be able to download or print a certificate once the form has been submitted.
Asistencia comercial
This activity is being provided independent of industry support.